Literature DB >> 21080857

The therapeutic potential of engineered human neovessels for cell-based gene therapy.

Luís Alvarez-Vallina1, Laura Sanz.   

Abstract

IMPORTANCE OF THE FIELD: Several works have shown the feasibility of engineering functional blood vessels in vivo using human endothelial cells and mural cells. In this context, the genetic modification of endothelial cells would ensure the secretion of a therapeutic protein into the systemic circulation for a prolonged period of time. AREAS COVERED IN THIS REVIEW: We discuss the different strategies aimed at the formation of long-lasting neovessels in vivo, using human endothelial and mural cells. The main focus is the potential of these constructs in gene therapy strategies for the in vivo production of therapeutic proteins. WHAT THE READER WILL GAIN: The reader will have an outline of the different types of cells that have been used for microvessel engineering in vivo, as well as scaffolds employed to seed these cells. We provide a critical review of their advantages and drawbacks, along with examples of their potential in cell-based gene therapy strategies. TAKE HOME MESSAGE: There is a real potential for neovessels derived from human endothelial and mural cells to be incorporated in clinical interventions, either as a cell-based gene therapy to produce a therapeutic protein or as a component of engineered tissue constructs in regenerative medicine.

Entities:  

Mesh:

Year:  2010        PMID: 21080857     DOI: 10.1517/14712598.2011.538378

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  2 in total

1.  Induction of erythropoiesis using human vascular networks genetically engineered for controlled erythropoietin release.

Authors:  Ruei-Zeng Lin; Alexandra Dreyzin; Kristie Aamodt; Dan Li; Shou-Ching S Jaminet; Andrew C Dudley; Juan M Melero-Martin
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

2.  In vivo secretion of anti-CD3 × anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement.

Authors:  Marta Compte; Laura Sanz; Luis Álvarez-Vallina
Journal:  Mol Ther       Date:  2015-04       Impact factor: 11.454

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.